Two new papers on the mitochondrial peptide MOTS-c land in the same week, one reporting protection of retinal blood vessels in diabetic mice, the other warning that the peptide's effects reverse depending on context. Human abundance data remain inconsistent and no clinical trial has tested supplementation.
Retatrutide, a triple GLP-1, GIP and glucagon receptor agonist, is in phase 3 trials with trial weight loss that one principal investigator compared to bariatric surgery. A separate BMJ case report describes refractory nausea in a woman injected with an unverified product reported to contain it.
Collagen peptides are one of the best-selling supplement ingredients in the world, with a forecast 7.2 percent annual growth rate through 2035. The current research pool behind that market includes a frozen-dough study, a product description, and no human trial at all.
GHK-Cu, the copper-binding tripeptide, has been studied for decades and sells for under $40 a vial, but the publicly available coverage is hedged mechanism talk, cell culture work and animal wound studies. A look at what three current sources actually claim, and what none of them establishes.
Semaglutide has randomized trial data behind it, which is more than most compounds sold under the word peptide. Here is what four recent studies reported, and the sizable gaps they leave open.
A September 2026 preprint identified 1,039 documented BPC-157 users and a roughly 33-fold rise in new users since 2020, while the named human studies behind the peptide involve 16 people and two people. Here is what the research actually reports, and the large amount it does not.
A market study projects 7.2% annual growth for glutathione through 2035 on beauty and longevity demand, while the FDA has posted a nationwide recall of compounded injectable glutathione over elevated endotoxin levels. Neither source cites a clinical trial for the claims the category is sold on.
Two large observational studies touch tirzepatide from very different angles: a three-year veterans cohort on cardiovascular events after stopping GLP-1 therapy, and a matched cohort on oral and periodontal outcomes. Neither demonstrates cause, and one does not isolate tirzepatide at all.
NAD+ is sold as both a clinic infusion and an oral precursor, but none of the current coverage names a human trial, a dose or an outcome figure. A New York medical examiner has ruled one infusion death a homicide, while dermatologists are still publicly asking whether the category is hope or hype.
An FDA advisory committee voted in July to recommend MOTS-c for the 503A Bulks List, but the vote carries no legal effect and the rulemaking has not started. None of the available coverage names a single human trial of the mitochondrial-derived peptide, its size or its result.
TB-500 is a seven-amino-acid fragment of thymosin beta-4, and FDA states the two are different substances. A review of the evidence finds a cell migration hypothesis, one unhelpful 2024 lab result, and no published human studies at all.
Semaglutide research now spans mouse lifespan experiments, a genetic link to male-pattern hair loss, and 400,000 Reddit posts mined for unreported symptoms. Here is what each of those studies actually reported, and what none of them established.
Recent collagen peptide research spans frozen dough stabilization and cell-culture hydrogel scaffolds, alongside a new consumer gummy launch. None of it reports a human clinical outcome, which is worth knowing before reading the marketing.
A preprint curating U.S. clinical notes found BPC-157 use rose 33-fold between 2020 and 2026, with pain and gastrointestinal conditions the most documented reasons. The authors say the records cannot establish efficacy, and the peptide's compounding status remains unresolved.
Retatrutide has not been approved and has no legal commercial supply, yet import reviewers logged eight shipments in two months, one declaring 222,930 pieces. Here is what the public record on the compound actually contains, and what it does not.
The FDA approved Mounjaro for cardiovascular risk reduction on the strength of SURPASS-CVOT, a trial of more than 13,000 participants that compared it head-to-head with Trulicity. Here is what that trial measured, what clinicians said about the mechanism, and the questions the researchers say remain open.
GHK-Cu has decades of mechanistic and cell-culture research behind it, and dermatologists say its wound-healing history is the most clinically established part. Controlled human trials on the aging-skin uses it is now marketed for remain thin.
Three recent reports touch semaglutide from different angles: an unexpected brain mechanism in mice, a combination experiment with an experimental fat-burning compound, and laboratory redesign of the peptide's structure. None of the three involved human participants.
Three recent studies touch on semaglutide, and none of them involved human participants. Here is what each one actually reported, and what the authors said still needs testing.
A randomized placebo-controlled trial reports improvements in hair gloss and elasticity after 24 weeks of low-molecular-weight collagen peptide GT, while a separate food-science paper tests fish skin collagen peptides as a cryoprotectant in frozen gluten. The two lines of research measure very different things, and neither supports a conclusion drawn from the other.
